The cluster shows a clear divergence: mega-passive funds (Morgan Stanley, Goldman Sachs) reduced exposure while quant/hedge funds (Point72, D.E. Shaw) initiated new positions. Monitor upcoming earnings for catalyst that could validate the quant thesis or confirm the passive sell-off rationale.
Executive Summary
Institutional activity in GSK during Q2 2026 was mixed: 29 buyers added $318.7M in new positions (led by Point72 and D.E. Shaw initiating large stakes), while 29 sellers reduced holdings by $478.9M (led by Morgan Stanley and Goldman Sachs trimming). The net selling pressure of ~$160M suggests institutional caution, though new quant/hedge fund positions signal some conviction in a turnaround thesis.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$160.2M
▲ Buyers (29)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Point72 | NEW | +100% | $139.1M | $139.1M |
| JPMorgan | DOUBLED | +260.2% | $110.1M | $78.7M |
| D.E. Shaw | NEW | +100% | $53.4M | $53.4M |
| UBS | ADD | +34.6% | $147.1M | $32.1M |
▼ Sellers (29)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | TRIM | -30.6% | $608.8M | -$207.4M |
| Goldman Sachs | TRIM | -33.6% | $529.2M | -$195.2M |
| Renaissance Technologies | EXIT | -100% | $17.2M | -$17.2M |
| Optiver Holding B.v. | NEAR_EXIT | -93.8% | $14.1M | -$13.3M |
Key Facts
- 29 buyers accumulated $493.4M in total positions (net change +$318.7M)
- 29 sellers reduced holdings by $478.9M (net change -$478.9M)
- Point72 initiated a new $139.1M position (2.65M shares)
- D.E. Shaw initiated a new $53.4M position (1.02M shares)
- Morgan Stanley trimmed 30.6% of its stake, selling $207.4M
- Goldman Sachs trimmed 33.6% of its stake, selling $195.2M
- Renaissance Technologies fully exited its $17.2M position
- JPMorgan doubled its stake, adding $78.7M in value
Financial Impact
Net institutional selling of approximately $160.2M during Q2 2026, with $318.7M in buying offset by $478.9M in selling
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Net selling by large passive managers suggests institutional caution on GSK's near-term outlook
- Quant fund inflows may be short-term tactical rather than conviction-based
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-GSK-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $51.15 | awaiting T+1 | — | — |
Oct 26, 2026 today | 6-K | $50.99 | awaiting T+1 | — | — |
Oct 26, 2026 today | 6-K | $51.11 | awaiting T+1 | — | — |
Oct 26, 2026 today | 6-K | $50.83 | awaiting T+1 | — | — |
Oct 21, 2026 5d ago | 6-K | $50.02 $51.21 | ▲ +2.38% | ▲ +3.56% | — |
Oct 19, 2026 7d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | — |
Oct 19, 2026 7d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | — |
Oct 15, 2026 11d ago | 6-K | $49.02 $49.51 | ▲ +1.00% | ▲ +2.11% | — |
Oct 14, 2026 12d ago | 6-K | $47.87 $49.02 | ▲ +2.40% | ▲ +2.12% | — |
Oct 13, 2026 13d ago | 6-K | $46.27 $47.87 | ▲ +3.46% | ▲ +4.54% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers